Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellaVision ABCLVSF 85 14-Day RSI is 78.76 as of Jul. 16, 2026. GuruFocus rates CLVSF with a GF Score™ of 85/100 and a GF Value™ of $22.04 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 867 Medical Devices & Instruments companies, CellaVision AB ranks worse than 53.17% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-16), CellaVision AB's 14-Day RSI is 78.76.
The industry rank for CellaVision AB's 14-Day RSI or its related term are showing as below:
CLVSF's 14-Day RSI is ranked worse than 53.17% of 867
companies
in the Medical Devices & Instruments industry
Industry Median: 48.54
vs CLVSF: 78.76
CellaVision AB (OTCPK:CLVSF) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
CellaVision AB 14-Day RSI Related Terms
CLVSF vs ABT, SYK, MDT: 14-Day RSI Comparison
For the Medical Devices subindustry, CellaVision AB's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where CellaVision AB's 14-Day RSI falls into.
CellaVision AB (OTCPK:CLVSF) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB (CLVSF) has a 14-Day RSI of 78.76 as of Jul. 16, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on CellaVision AB and its competitors. According to the industry distribution chart, CellaVision AB ranks #461 out of 867 companies in the Medical Devices & Instruments industry, placing it in the top 53.2%.
Is CellaVision AB's 14-Day RSI too high?
CellaVision AB's current 14-Day RSI is 78.76. The Medical Devices & Instruments industry median 14-Day RSI is 48.54. CellaVision AB's value of 78.76 is 62.3% above this industry median. Based on the distribution chart, CellaVision AB ranks #461 out of 867 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, CellaVision AB has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's 14-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #461 out of 867 companies for 14-Day RSI. This places CellaVision AB in the lower half of its industry. The industry median 14-Day RSI is 48.54. CellaVision AB's value of 78.76 is 62.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 48.54, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current 14-Day RSI of 78.76 is 62.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current 14-Day RSI is 78.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CLVSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $22.04, compared to a current price of $14.00 — trading 36.5% below its estimated fair value. The current 14-Day RSI is 78.76 and 62.3% above the Medical Devices & Instruments industry median of 48.54. CellaVision AB's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For CellaVision AB (CLVSF), the current 14-Day RSI is 78.76 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CLVSF) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $14.00 is trading 36.5% below its estimated GF Value™ of $22.04.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CLVSF:
14-Day RSI: 78.76
GF Value™: $22.04 vs. price of $14.00 (36.5% below fair value)
Industry Position: 62.3% above the Medical Devices & Instruments median (#461 of 867)
No single metric tells the full story. See the CLVSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
85GF Score
Get the complete analysis for CLVSF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVSF has been successfully added to your 
